Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
XNK Therapeutics logo — INDIVIDUALIZED NK CELL THERAPIES

XNK Therapeutics

INDIVIDUALIZED NK CELL THERAPIES

Founded 2012 Sweden Sweden 9 employees Grant Total: $197.70M Health and Wellness, Pharmaceutical

General Information

Company Name XNK Therapeutics
Founded Year 2012
Location Sweden Sweden +1
Employees 9
Industries Health and Wellness, Pharmaceutical
Funding Stage Grant
Social

Get notified when XNK Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About XNK Therapeutics

XNK Therapeutics is a clinical-stage biotechnology company with a mission to develop individualized and unique natural killer (NK) cell-based cancer therapies. Their R&D pipeline focuses on addressing unmet medical needs in hematological malignancies and solid tumors. Their most advanced product candidate, evencaleucel, is currently undergoing evaluation in a phase II clinical study in combination with the CD38 monoclonal antibody, isatuximab, as consolidation therapy for newly diagnosed multiple myeloma patients following stem cell transplantation. At the heart of XNK is a team of world-renowned NK cell experts and pioneers in the field. The company benefits from a proprietary technology platform with a tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. This strategic positioning allows XNK to develop transformational autologous NK cell-based therapies and brings new hope to cancer patients worldwide. Founded in 2011 and headquartered in Sweden, XNK Therapeutics received a grant investment of kr1.70M from Vinnova on 10 October 2023. This investment further solidifies the company's position and potential to make a significant impact in the pharmaceutical industry. With its cutting-edge approach and strong partnerships, XNK is well-positioned to make a difference in the fight against cancer.

Taxonomy: NK cell therapy, Cancer treatment, Clinical-stage, Hematological malignancies, Solid tumors, Evencaleucel, Isatuximab, Stem cell transplantation, Multiple myeloma, Proprietary technology platform, GMP facility, Karolinska Institute, Autologous therapy, Clinical study

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
10 Oct 2023
Non Equity Assistance •••••• 1 •••• •••• 12 Jul 2023
Venture Round •••••• 1 •••• •••• 29 Mar 2022
Funding Round •••••• - 12 Apr 2021

XNK Therapeutics Alternatives & Competitors

XNK Therapeutics vs
Lyell Immunopharma
Lyell Immunopharma United States

At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.

Unknown
229 employees
Biotechnology
XNK Therapeutics vs
Smart Immune
Smart Immune France

Pioneering thymus-empowered T-cell platform to fight cancer and infection

Grant
35 employees
Biotechnology, Health Care
XNK Therapeutics vs
Tigen
Tigen Switzerland

We are a biotech company in the field of cell therapies to cure cancer - Smart Cells for Life

23 employees
Biotechnology, Health Care
Also compare with: XNK Therapeutics vs Acepodia Acepodia

FAQ About XNK Therapeutics

INDIVIDUALIZED NK CELL THERAPIES
XNK Therapeutics was founded in 2012.
XNK Therapeutics is headquartered in Sweden.
XNK Therapeutics operates in the following industries: Health and Wellness, Pharmaceutical.
XNK Therapeutics has approximately 9 employees.
XNK Therapeutics has completed 4 funding rounds, raising a total of $197.70M. The latest funding stage is Grant.
Top alternatives and competitors to XNK Therapeutics include Lyell Immunopharma, Smart Immune, Tigen, TC BioPharm , Acepodia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XNK Therapeutics and Lyell Immunopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors XNK Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes